ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes <i>BRCA1</i> and <i>BRCA2</i>, with many more potential applications under study and in clinical trials...

Full description

Bibliographic Details
Main Authors: Nicholas R. Jette, Mehul Kumar, Suraj Radhamani, Greydon Arthur, Siddhartha Goutam, Steven Yip, Michael Kolinsky, Gareth J. Williams, Pinaki Bose, Susan P. Lees-Miller
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
atm
olaparib
atr
parp
parp inhibitor
prostate cancer
pancreatic cancer
lung cancer
Online Access:https://www.mdpi.com/2072-6694/12/3/687

Internet

https://www.mdpi.com/2072-6694/12/3/687

Similar Items